CytRx Corporation (CYTR)

Oncology Corporate Profile

Stock Performance

0.6060
0.0080

HQ Location

11726 San Vicente Blvd, Suite 650
Los Angeles, CA 90049

Company Description

CytRx Corporation is a biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon our small-molecule molecular 'chaperone'? amplification technology.

Website: http://www.cytrx.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
aldoxorubicinanthracycline (doxorubicin prodrug)2nd line metastatic soft tissue sarcomaIII
aldoxorubicinanthracycline (doxorubicin prodrug)Glioblastoma Multiforme (GBM)II
aldoxorubicinanthracycline (doxorubicin prodrug)Small Cell Lung Cancer (SCLC)II

View additional information on product candidates here »

Source: http://www.cytrx.com

Recent News Headlines

CytRx to Present Data at the European Society for Medical Oncology 2016 Congress from Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial

9/13/2016 11:29 am

(Yahoo! Finance) Sept 12, 2016 - CytRx Corporation today announced that results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress being held in Copenhagen, Denmark, from October 7-11, 2016.

CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer

9/7/2016 11:21 am

(Yahoo! Finance) Sept 7, 2016 - CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that it has reached its enrollment target of 132 patients for the company's global Phase 2b clinical trial of aldoxorubicin in patients with previously treated small cell lung cancer (SCLC).

CytRx Announces Initial Results of Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcoma; Subsequent Analysis to Be Announced Fourth Quarter 2016

7/12/2016 10:22 am

(The Business Journals) July 11, 2016 - CytRx Corporation today announced the results of an analysis of its global, randomized, Phase 3 clinical trial of aldoxorubicin compared to investigator's choice therapy in patients with relapsed or refractory soft tissue sarcomas (STS).

Feuerstein: CytRx Sarcoma Drug Flops Late-Stage Clinical Trial

7/12/2016 08:51 am

(TheStreet) July 11, 2016 - The aldoxorubicin sarcoma study failure leaves CytRx with a depleted pipeline and 40 cents per share in cash.

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

5/16/2016 10:00 am

(TheStreet) May 16, 2016 - A type of common bacteria re-engineered by Aduro Biotech to engage the immune system to kill pancreatic cancer failed a mid-stage study, the company announced Monday.

CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail

5/11/2016 12:14 pm

(TheStreet) May 10, 2016 - CytRx is in a countdown to failure. Data from CytRx's phase III study of aldoxorubicin for the treatment of patients with soft-tissue sarcoma are being analyzed right now, with results expected toward the end of June.

South Africa Negotiating With Roche To Cut Cancer Drug Prices

5/10/2016 11:03 am

(Reuters) May 10, 2016 - South Africa is in talks with pharmaceutical firm Roche to reduce the price of its breast cancer drug Herceptin, which cost 500,000 rand ($32,745) a year to treat one person and was unaffordable to most women, the health minister said on Tuesday.

CytRx Corporation Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis

4/4/2016 11:27 am

(Morningstar) Apr 4, 2016 - Top-line progression-free survival data expected in June 2016.

FDA Approves Teva Asthma Treatment

3/24/2016 11:05 am

(Globes [Israel]) Mar 23, 2016 - The US Food and Drug Administration (FDA) has approved Teva's CINQAIR injection for treating asthma. The treatment is expected to become commercially available to patients, by prescription, during the second quarter of 2016.

Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma

3/24/2016 11:02 am

(Yahoo! Finance) Mar 24, 2016 - Updated guidelines recognize the ONIVYDE regimen as a standard-of-care for treatment of patients with post-gemcitabine metastatic pancreatic cancer.

BRCA Clinics Expand Further Beyond Breast Cancer

2/23/2016 07:01 am

(Wall Street Journal) Feb 22, 2016 - A new clinic in San Francisco is opening with an unusual mission: to provide care for people affected by mutations in two particular genes linked to a high risk of cancer. The move highlights the ways growing knowledge about the genetics of the disease is reshaping care for patients.

FDA Grants TapImmune Fast Track Designation For Lead Vaccine In Ovarian Cancer

2/3/2016 11:04 am

(NASDAQ/RTTNews.com) Feb 3, 2016 - TapImmune Inc., a clinical-stage immuno-oncology company, said that the U.S. Food & Drug Administration or FDA has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer.

Poor or Minority Adolescent and Young Adult Patients Are Less Likely to Beat Hodgkin Lymphoma

1/29/2016 12:00 pm

(AACR) Jan 29, 2016 - Patients who are diagnosed with Hodgkin lymphoma between the ages of 15 and 39 are less likely to survive the disease if they are black, Hispanic, or live in a neighborhood with low socioeconomic status, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

CytRx Announces the Completion of Enrollment in Pivotal Global Phase 3 Trial Ahead of Schedule

12/4/2015 11:28 am

(TheStreet) Dec 1, 2015 - Top-line progression-free survival data now expected in the first half of 2016.

FDA Approves New Treatment for Advanced Pancreatic Cancer

10/22/2015 11:04 am

(FDA.gov) Oct 22, 2015 - The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

ImmunoGen, Roche Gastric Cancer Drug Fails Study

10/22/2015 11:04 am

(Reuters) Oct 22, 2015 - ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study.

AstraZeneca, Lilly Expand Immuno-Oncology Collaboration

10/22/2015 11:04 am

(Genetic Engineering & Biotechnology News) Oct 22, 2015 - Eli Lilly and AstraZeneca said today they are expanding a five-month-old immuno-oncology collaboration by exploring across their portfolios the safety and efficacy of additional new combination therapies for patients with solid tumors.

Can Aspirin Stop Cancer Returning? World's Largest Clinical Trial Begins

10/22/2015 11:04 am

(The Telegraph [UK]) Oct 22, 2015 - Study to determine if taking aspirin - already proven to help prevent heart attacks and strokes - every day can stop cancers from coming back.

Vitamin B3 Derivative Cuts Risk of New Skin Cancers

10/22/2015 11:04 am

(University of Sydney [AU]) Oct 22, 2015 - A year of treatment with nicotinamide, a form of vitamin B3, significantly lowered the risk of common, non-melanoma skin cancer in high-risk patients, according to University of Sydney research published today in the New England Journal of Medicine.

Researchers Suss out Brain Tumors, and Therapy Response, with New Metabolic PET Tracer

10/22/2015 11:04 am

(Stanford Medicine) Oct 21, 2015 - Locating a tumor hiding in a thicket of brain cells can be a tricky proposition.

NHS to Fund World’s Largest Study Into Effect Of Aspirin On Cancer

10/22/2015 06:04 am

(The Guardian [UK]) Oct 21, 2015 - The world’s largest clinical trial to investigate whether taking aspirin every day stops the recurrence of some of the most common cancers is to be funded by Cancer Research UK and the NHS.

Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations

10/22/2015 06:04 am

(MarketWatch) Oct 22, 2015 - Eli Lilly and Company and AstraZeneca today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

Clinton Questions Plans For Health Insurers To Merge

10/21/2015 12:01 pm

(Washington Post/Associated Press) Oct 21, 2015 - Hillary Rodham Clinton warned Wednesday that two major health insurers preparing multibillion dollar acquisitions could tip “the balance of power” too far away from consumers.

Genetic Testing Company 23andMe Returns to Market

10/21/2015 12:01 pm

(TIME) Oct 21, 2015 - 23andMe is back as the only company providing genetic profiling information directly to consumers—with some very important changes.

Glaxo, Pfizer, U.K. Form $100 Million Alzheimer's Research Fund

10/21/2015 12:00 pm

(Bloomberg) Oct 20, 2015 - GlaxoSmithKline Plc, Pfizer Inc. and other pharmaceutical companies agreed to invest in a $100 million fund with the U.K. government to explore new approaches to Alzheimer’s disease and other forms of dementia, a field marred by drug failures.

Biogen to Cut 880 Jobs – 400 In Mass. – In Restructuring

10/21/2015 12:00 pm

(Boston Globe) Oct 21, 2015 - Cambridge biotech giant Biogen Inc. said Wednesday that it would cut about 880 jobs, including 400 in Massachusetts, and terminate several drug research programs this year as it struggles to adjust to mounting competition and a fresh setback to a key multiple sclerosis drug.

Cancer Society Updates Mammogram Guidelines

10/21/2015 11:01 am

(KHN Morning Briefing) Oct 21, 2015 - The American Cancer Society said Tuesday that women should start getting the screening test at a later age -- 45 instead of 40 -- and fewer of them.

Opinion: Lawmakers Must Stand Up For Medicare Cancer Care In Michigan

10/21/2015 11:00 am

(MLive.com) Oct 19, 2015 - At least 31 oncology clinics here have closed since 2008, the second highest number of any state. Another 42 have reported they are struggling financially.

Bristol-Myers, Novartis Score Big In Major Blood Cancer Drug Cost-Benefit Analysis

10/21/2015 11:00 am

(BioPharma Dive) Oct 19, 2015 - The National Comprehensive Cancer Network (NCCN) has completed an "Evidence Block" for multiple myeloma and chronic myelogenous leukemia (CML)—the first in a series of such blocks attempting to weight cancer medications' costs versus their relative benefits.

CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform

6/30/2015 12:08 pm

(Yahoo! Finance) June 30, 2015 - Next generation linker technology designed to improve the safety and efficacy of oncology therapies, including immunotherapies and high potency chemotherapeutics up to 1,000 times more powerful than traditional drugs; first drugs derived from Cytrx's LADR™ platform expected to enter clinical development in 2016.

Lilly Shares Sizzle as Investors Await Alzheimer's Data

6/12/2015 11:03 am

(Reuters) June 11, 2015 - Shares of Eli Lilly and Co have jumped 10 percent this week, confounding many industry experts, amid speculation investors were placing bets ahead of expected long-term data on an Alzheimer's disease treatment once considered a dud.

CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma

1/22/2015 11:21 am

(Yahoo! Finance) Jan 22, 2015 – Aldoxorubicin demonstrates 2-fold increase in likelihood of surviving more than 2 years versus doxorubicin and 27% reduction in the risk of death.

CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients

1/20/2015 12:11 pm

(NASDAQ) Jan 20, 2015 - CytRx Corporation today announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's aldoxorubicin clinical trials.

CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment For HIV-Related Kaposi's Sarcoma (KS)

1/8/2015 11:57 am

(Yahoo! Finance) Jan 8, 2015 - CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

CytRx Says FDA to Decide on Study Enrollments in January

1/7/2015 11:57 am

(Reuters) Jan 6, 2015 - CytRx Corp said interim data showed its experimental brain cancer drug was effective in a mid-stage study and a partial clinical hold on enrollment could be lifted this month.

Cytrx Cancer Drug Shows Promise in Trial, Shares Rise

1/6/2015 11:16 am

(Reuters) Jan 6, 2015 - Cytrx Corp said interim data showed its experimental cancer drug was effective in a mid-stage trial on patients with a deadly form of brain cancer, sending its shares up 33 percent before the bell.

CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials

12/3/2014 12:12 pm

(StreetInsider) Dec 3, 2014 - CytRx Corporation today announced that the Company has received written notice from the United States Food and Drug Administration (FDA) that its clinical trials for aldoxorubicin have been placed on partial clinical hold.

CytRx's Cancer Drug Trial on FDA Partial Hold After Patient Death

11/18/2014 11:49 am

(NASDAQ/RTTNews.com) Nov 18, 2014 - Cancer drug maker CytRx Corp., Tuesday said the FDA has placed a partial hold on clinical trials of its investigational cancer drug aldoxorubicin, following the death of a patient.

CytRx to Present Data From Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting

10/17/2014 11:05 am

(CNBC) Oct 17, 2014 - Due to the longer than expected survival of patients in the clinical trial, there have not been a sufficient number of survival events to enable the Company to report data on overall survival, a secondary endpoint of the study.

CytRx Initiates Phase 1b Clinical Trial With Combination of Aldoxorubicin and Gemcitabine in Patients With Metastatic Solid Tumors

10/9/2014 11:36 am

(Yahoo! Finance) Oct 9, 2014 - CytRx Corporation today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

CytRx Gets Multiple Orphan Drug Designations For Aldoxorubicin

10/3/2014 11:11 am

(NASDAQ/RTTNews.com) Sept 29, 2014 - CytRx Corp. Monday said the U.S. Food and Drug Administration or FDA has granted multiple orphan drug designations for its drug candidate, aldoxorubicin, in three indications, which include glioblastoma multiforme or GBM, small cell lung cancer and ovarian cancer.

CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin For the Treatment of Relapsed/Refractory Small Cell Lung Cancer

9/30/2014 01:15 pm

(San Francisco Business Times) Sept 30, 2014 - Completion of enrollment expected in 2015; progression-free survival data expected in mid-2016.

CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas

9/9/2014 12:10 pm

(CytRx) Sept 9, 2014 - CytRx Corporation today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus ifosfamide/mesna as a first-line treatment in subjects with various sarcomas.

CytRx Is Pouring Money into R&D of Cancer-Fighting Drugs

9/2/2014 12:12 pm

(Los Angeles Times) Aug 31, 2014 - CytRx is in the middle of recruiting 400 patients worldwide for its pivotal Phase 3 clinical trial of a second-line treatment for soft-tissue sarcoma.

Biotech Stock Mailbag: Threshold, Galena, CytRx

8/22/2014 11:54 am

(The Street) Aug 22, 2014 – What are your thoughts on Threshold Pharmaceuticals?

CytRx Highlights Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft Tissue Sarcoma

5/28/2014 11:43 am

(TheStreet) May 28, 2014 - Results to be updated in oral presentation at ASCO 2014; aldoxorubicin demonstrated highly statistically significant increases in PFS, PFS at 6 months and ORR, compared to doxorubicin.

CytRx Highlights Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft Tissue Sarcoma

5/28/2014 06:04 am

(TheStreet) May 28, 2014 - Results to be updated in oral presentation at ASCO 2014; aldoxorubicin demonstrated highly statistically significant increases in PFS, PFS at 6 months and ORR, compared to doxorubicin.

CytRx to Present Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma at Upcoming Research and Development Day

4/28/2014 12:01 pm

(Reuters) Apr 28, 2014 - CytRx Corporation today announced that it will be presenting updated progression-free survival and overall survival results from its completed Phase 1b/2 clinical trial of aldoxorubicin in soft tissue sarcoma.